January 2010
Worldwide Biotech;Jan2010, Vol. 22 Issue 1, p7
Trade Publication
The article reports on positive initial results posted by Novavax Inc. from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of its 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax has partnered with Avimex Laboratories to conduct the study as part of registration of the vaccine in Mexico and other countries. All three dose levels of the vaccine were well-tolerated and showed no systematic side effects.


Related Articles

  • Novavax reports positive results from influenza vaccine study.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p8 

    The article reports that biotechnology company Novavax Inc. reports positive results of its two-state pivotal study to evaluate the safety and immunogenicity of its unadjuvanted 2009 A/H1N1 virus-like particle pandemic influenza vaccine. According to the company, data shows that safety and...

  • A Caution About Giving Tamiflu To Children.  // Child Health Alert;Nov2009, Vol. 27, p4 

    The article discusses research on administering tamiflu to children. It references a study by R. M. Parker et al, published in the September 23, 2009 issue of the "New England Journal of Medicine." It reports the case of a 6-year-old with H1N1 flu who was prescribed with liquid Tamiflu but the...

  • Encephalitis in a child with H1N1 infection: First case report from India. Kulkarni, Rajesh; Kinikar, Aarti // Journal of Pediatric Neurosciences;Jul-Dec2010, Vol. 5 Issue 2, p157 

    Neurological complications have been described with seasonal influenza infection. We report encephalitis manifesting as seizures in a child with confirmed H1N1 infection. Treatment with oseltamivir was started. Child was discharged without any neurological sequelae.

  • Pharmacologic Considerations for Oseltamivir Disposition. Abdel-Rahman, Susan M.; Newland, Jason G.; Kearns, Gregory L. // Pediatric Drugs;2011, Vol. 13 Issue 1, p19 

    Across much of the world, pandemic H1N1 infection has produced a significant healthcare crisis, reflected in significant morbidity and mortality. Statistics reveal that infection-associated deaths among individuals without pre-existing conditions (e.g. immunosuppression) are clustered in...

  • H1N1 dosing and efficacy. Elliott, William T. // Primary Care Reports;Feb2010 Pharmacology Watch, p2 

    The article focuses on the studies that was published in the December 17, 2009 issue of "New England Journal of Medicine," which revealed that a dose of H1N1 vaccine is already effective for those 3 years-old and above. The first study included 240 individuals which were divided to receive 15...

  • Data Support Co-administration of Flu Shots.  // BioWorld Today;10/12/2009, Vol. 20 Issue 196, p4 

    The article reports on the statement issued by Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, regarding the safety of the simultaneous administration of H1N1 swine-origin influenza A and seasonal flu vaccine. He also announced the clinical trials...

  • A novel sequence-based antigenic distance measure for H1N1, with application to vaccine effectiveness and the selection of vaccine strains. Pan, Keyao; Subieta, Krystina C.; Deem, Michael W. // PEDS: Protein Engineering, Design & Selection;Mar2011, Vol. 24 Issue 3, p291 

    H1N1 influenza causes substantial seasonal illness and was the subtype of the 2009 influenza pandemic. Precise measures of antigenic distance between the vaccine and circulating virus strains help researchers design influenza vaccines with high vaccine effectiveness. We here introduce a...

  • Oseltamivir for the treatment of H1N1 influenza during pregnancy. Beigi, RH; Pillai, VC; Venkataramanan, R; Caritis, SN // Clinical Pharmacology & Therapeutics;Oct2015, Vol. 98 Issue 4, p403 

    Pregnancy heightens the risk of adverse outcomes from influenza infections. This is true for both seasonal epidemics as well as occasional pandemics. Seasonal influenza vaccines are the focus of disease prevention and are recommended for all pregnant women in any trimester of pregnancy and...

  • Losing the Opportunity to Study Influenza Drugs. Meyerhoff, Andrea; Lietman, Paul // JAMA: Journal of the American Medical Association;3/3/2010, Vol. 303 Issue 9, p878 

    The author considers the claims about the efficacy of the peramivir drug in preventing influenza A (H1N1). Information on the development of peramivir is given. The author shares that peramivir can be obtained by three mechanisms, namely, other drugs not approved by the U.S. Food and Drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics